Trial of RD133 for mesothelin-positive tumors after prior treatment
Part of Cancer clinical trials.
This early-stage trial tests whether RD133 can be safe and effective for people whose solid tumors have a high “mesothelin” marker and that have not responded to at least two standard treatments. If you qualify, you’ll be checked closely for side effects and whether the tumor responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and agree by signing an ethics-approved consent form
- Your tumor has more than 25% mesothelin-positive cells on prior tissue testing
- Your cancer has not responded to the last of at least two prior standard treatments
- You have at least one measurable tumor spot on scan, and you’re expected to live at least 12 weeks
- Your overall strength/health is limited enough that your ECOG score is 2 or less
- Your blood counts and organ tests (kidney, liver, heart, bleeding risk) meet the study thresholds
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests RD133, an experimental treatment, in adults whose solid tumors are mesothelin-positive and have come back or not responded to prior standard therapies. It aims to see how well RD133 can control these cancers and what side effects it causes.
This clinical trial tests an experimental drug called HY05350 for people with advanced solid tumors that have a specific protein (mesothelin). It aims to see if the drug is safe and effective for cancers that have not responded to standard treatments.
This trial tests a new type of immune cell therapy made from donor cells that are trained to target two specific proteins found on mesothelioma tumors. The goal is to see if these cells can safely shrink tumors or slow the disease when given directly into the chest or belly area.
This trial tests an experimental drug called ISM6331 for people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The drug targets a specific cell pathway (Hippo) that may be involved in tumor growth.
This trial tests a new drug called SY001, which targets a protein called mesothelin found on some cancer cells. It is designed for people with advanced ovarian or pancreatic cancer who have already tried other treatments and whose tumor tissue has mesothelin.
This trial tests a new treatment called KT032, which are special immune cells (CAR-T cells) designed to attack cancer cells that have a protein called mesothelin. It is for people with advanced solid tumors, especially those that have spread to the abdomen, who have run out of standard options.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.